CONDITIONAL INTERNALIZATION OF PEGYLATED AGENTS BY PRETARGETING BI-SPECIFIC PEG-BINDING ANTIBODIES FOR DIAGNOSIS AND THERAPY

Title:

CONDITIONAL INTERNALIZATION OF PEGYLATED AGENTS BY PRETARGETING BI-SPECIFIC PEG-BINDING ANTIBODIES FOR DIAGNOSIS AND THERAPY

Document Type and Number:

WIPO Patent Application WO/2018/217459

Kind Code:

A3

Abstract:

A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also provided is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. A kit that contains a PEG engager and a PEGylated anti-cancer agent is also disclosed. Further disclosed are methods for imaging cells and diagnosing cancer by administering a PEG engager followed by a PEGylated imaging agent. Another kit is proivided that includes the PEG engager and the PEGylated imaging agent.

More Like This:

WO/2007/011091	MONOCLONAL ANTIBODY FOR HIPPURIC ACID ANTIGEN
WO/2003/086286	TREATMENT OF TYPE 1 DIABETES BEFORE AND AFTER EXPRESSION OF PREDISPOSITION MARKERS
JP2007063179	MONOCLONAL ANTIBODY TO NITROBENZENESULFENYL GROUP-CONTAINING TRYPTOPHAN AND ANTIBODY COLUMN USING THE ANTIBODY

Inventors:

ROFFLER STEVE (TW)
CHENG TIAN-LU (TW)
SU YU-CHENG (TW)
CHUANG KUO-HSIANG (TW)

Application Number:

PCT/US2018/031784

Publication Date:

February 07, 2019

Filing Date:

May 09, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

ROFFLER STEVE (TW)
ACADEMIA SINICA (TW)

International Classes:

C07K16/44; A61K39/00; A61P35/00; C07K16/28; C07K16/30; G01N33/574

Foreign References:

US20170056523A1	2017-03-02
US20120282280A1	2012-11-08
US20060104899A1	2006-05-18

Other References:

KAO, C. H. ET AL.: "One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles", BIOMATERIALS, vol. 35, 8 September 2014 (2014-09-08), pages 9930 - 9940, XP029070179, DOI: doi:10.1016/j.biomaterials.2014.08.032
SU , Y.-C. ET AL.: "Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy", NATURE COMMUNICATIONS, vol. 8, no. 15507, 8 June 2017 (2017-06-08), pages 1 - 12, XP055576779, DOI: DOI: 10.1038/ncomms15507

Attorney, Agent or Firm:

WIDOM, Russell, L. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: FURNITURE WITH REMOVABLE ELECTRONICS RACK

Next Patent: A MIXER FOR DISPENSING A MULIT-COMPONENT MATERIAL